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Abstract
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Nocturnal enuresis is involuntary voiding that occurs exclusively at night, after most
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th
Available online: 30 June 2022 children have stopped. For the diagnosis of primary monosymptomatic enuresis, at least

three episodes of bed wetting in a patient who has never been dry for more than six

Keywords

months are required (PME). Despite a 15 % annual maturation rate, 0.5 % of all
instances continue throughout adulthood, with significant effects for self-esteem.



Fluoxetine

Behavioral and motivational therapy, alarm aids, and pharmacotherapy have all been



Nocturnal enuresis

recommended as therapeutic options for PME. Desmopressin or antimuscarinics like



Incontinence

propiverine or oxybutynin are the most common medical treatments for PME. Response



Arousal and sleep

failure to these medications is one of the issues in the management of PME. In recent
literature, the influence of medicines that modulate serotonin levels, such as selective
serotonin reuptake inhibitors (SSRIs), on urination has been reported. These findings
show that SSRIs might be used to treat nocturnal enuresis without the dangerous cardiac
arrhythmia that tricyclic antidepressants cause or the hyponatremia that long-term
desmopressin therapy causes. The goal of our research was to look at the role of
fluoxetine in the treatment of enuresis in children.
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Introduction

Review

Response

failure

to

pharmacological

I. Terminology and social impact

treatments including desmopressin is one of the
challenges

in

the

therapy

of

In children, enuresis is a prevalent medical

primary

problem. It influences millions of children

monosymptomatic enuresis (PME), particularly in

worldwide and is connected with a considerable

teenagers. Although there is a roughly 15%

detrimental impact on self-esteem and health-

spontaneous remission rate each year, around one-

related quality of life (1) .

third of all children with NE have a condition that

Nocturnal enuresis is defined as discrete

is resistant to first-line therapy, prompting the

episodes of urinary incontinence during sleep in

development of novel therapeutic alternatives.

children older than 5 years of age in the absence of

Selective serotonin reuptake inhibitors

congenital or acquired neurologic disorders.

used

Enuresis is classified as either monosymptomatic

depression

and

enuresis (MSE) or nonmonosymptomatic enuresis

(OCD),

have

(NMSE). MSE is characterised as enuresis in

minimal cardiovascular toxic effects and low

children who do not have any other LUTS or a

overdose risks, making them suitable for usage in

history

children and teenagers. Fluoxetine is the first

characterised as enuresis with any daytime LUTS

SSRI to be approved in USA for the management

(2). Daytime LUTS that point to NMSE include

of Major Depressive Disordres and was available

incontinence,

in the market in 1987.

discomfort, and holding techniques.

(SSRIs),

which

primarily

for

have

treatment

obsessive-compulsive

of

been

disorder

of

bladder

dysfunction.

frequency,

genital

NMSE

or

is

LUT

The purpose of the current review was to

MSE is further classified as primary and

summarize the current modalities of management

secondary. Primary MSE affects children who

of nocturnal enuresis with their success rates and

have never acquired a satisfactory period of

limitations and to illustrate the clinical role of

nocturnal dryness (~80% of enuretic children fulfil

fluoxetine in treating primary nocturnal enuresis.

this criterion). Secondary enuresis occurs when a
child develops enuresis after a dry interval of at
least 6 months (3) .

Methods
This review was performed by evaluating

Enuresis is a prevalent disease, with an

the literature on nocturnal enuresis published

estimated 7 million children suffering from it in

between 1970 and 2020, available via PubMed and

the United States alone. According to a major

using

enuresis",

longitudinal study conducted in the United

"fluoxetine", "pediatric", "review" and "treatment".

Kingdom, at least 20% of children in the first

the

keywords

"nocturnal

grade wet the bed on occasion, and 4% wet the bed
twice or more every week. (4). There is no
accurate number about the prevalence in Egypt.
At the age of five, roughly 15% of
children will experience some degree of overnight
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wetness, with a spontaneous resolution rate of

of these essential domains is assumed to be the

approximately 15% every year (5). As a result,

cause of enuresis.

only about 1% to 2% of teens will still wet the bed

Regardless of urine output, there appears

at the age of 15 (6). It has also been demonstrated

to be a subgroup of children with primary MSE

that the longer an enuresis lasts, the less likely it is

who have nocturnal bladder overactivity (11).

to resolve spontaneously (7).

Nearly half of treatment failures with conventional

Enuresis appears to be more prevalent in

therapy (desmopressin or wetness alarm) had

males than in girls, according to most reports,

normal daytime bladder function but substantial

which show a 2:1 ratio (8). It is widely

detrusor overactivity during sleep, resulting in

acknowledged that by adolescence, both boys and

enuresis, according to Yeung et al. (1999). Almost

females have equal frequency.

no one in this group of kids developed nocturnal

For the kid and its caregivers, nocturnal
enuresis has major secondary psychological,

polyuria.
The bladder capacity of children with

emotional, and social implications. As a result,

enuresis

(including

those

without

daytime

therapy is recommended starting at the age of six

symptoms) has been found to be lower than that of

years old, taking into account mental health,

age-matched controls (12) It appears that the

familial expectations, social concerns, and cultural

reduced bladder capacity is functional rather than

background.

anatomic. This was demonstrated in a study in

Psychosocial difficulties, low self-esteem,

which bladder capacity in children with enuresis

dread of sleepovers, and social isolation can all be

was measured in the awake state as well as under

symptoms of NE. NE is a socially and mentally

general anaesthesia and compared to functional

burdensome illness that can cause bullying and a

bladder capacity in controls (13). The average

reluctance to participate in social activities like

volume of urine voided by enuretic children in the

overnight stays (9). NE is the most frequent

waking state was lower than that of controls.

chronic condition in children, second only to

Enuretic children, on the other hand, had identical

asthma, and the third most unpleasant life event a

mean bladder volumes to awake controls when

kid can face (10).

volumes were assessed after general anaesthesia.
In nocturnal enuresis, increased nighttime

II. Pathophysiology

urine output appears to play a key role (14). The

Enuresis is thought to be caused by a

diurnal rhythm of urine production leads in a

maturational delay in the final development of

relative drop in nocturnal diuresis to around 50%

bladder control. The bladder (i.e., reduced

of daytime levels in children and adolescents

nocturnal bladder capacity), the kidney (i.e.,

without enuresis (15). A nocturnal circadian peak

nocturnal polyuria), and the brain (i.e., a disorder

of antidiuretic hormone (ADH) production from

affecting arousal from sleep) are the three organ

the posterior pituitary gland, which regulates free

systems implicated in the aetiology of enuresis.

water excretion, is likely to be the dominating

The disruption or maturational lag in one or more

mechanism.

Published by Mansoura Medical Journal, 2023
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Whatever the reason, urine output that is

that polysomnographic differences must represent

supposed to decrease at night due to these

high arousal thresholds. Even if two people have

circadian systems fails to do so, resulting in

the same distribution and proportion of the various

nocturnal polyuria, which might surpass the

sleep phases, their arousal thresholds might be

bladder's functional capacity and cause an enuretic

vastly different. (19).

episode. Rasmussen et al. (1996) shown that

Wolfish et al. studied the arousability of

increasing nocturnal urine production can indeed

boys with NE and healthy age-matched controls in

induce enuresis in healthy youngsters (16).

1997. In order to do this, auditory stimuli of

Despite this seemingly straightforward

increasing intensity were applied at all phases of

causal link, it is obvious that nocturnal polyuria

sleep. This was the first study to show that

and

extremely

children with NE have a harder time waking up in

nocturnal

a clinical setting. In healthy controls, the success

polyuria is not present in all children with enuresis,

rate of waking was 98/239, compared to just

and nocturnal ADH may be normal in those who

25/269 in children with enuresis. This study also

do (17).

proved that, as expected, it is significantly more

ADH

complicated

responsiveness
phenomena,

are

because

difficult to wake up both controls and NE-children
III. Arousal and Sleep :

in the early hours of the night (20).

The most essential pathophysiological

Other sleep studies, on the other hand,

element is a high arousal threshold. Neither

reveal that children with and without enuresis have

detrusor overactivity nor nocturnal polyuria can

similar sleep patterns. (21).

explain why a kid with enuresis is unable to wake

Yeung et al work in Hong Kong is widely

up and void before a wetting episode. Both

cited as the first to establish that frequent,

detrusor contractions and bladder distension are

ineffective

well-known arousal stimuli.

bedwetting children's sleep. (22) . Although these

arousal

reactions

might

disrupt

Enuresis patients are frequently described

children seemed to be heavy sleepers, a study of

by their parents as extremely deep sleepers. Family

35 children with therapy-resistant MSE in Hong

members of patients on alarm therapy frequently

Kong found that they experienced more total light

face this dilemma, as parents arise from their sleep

sleep

while their enuretic kid sleeps through the alert.

fragmentation than deep sleep (stage III/IV non-

(18). Enuresis was associated with a subjectively

REM).(22).

(stage

I/II

non-REM)

with

sleep

high arousal threshold and severe confusion upon

The cerebral cortex received afferent input

rising from sleep, according to Nevéus et al.

from the sleep OAB, which was accompanied by

(1999), who collected questionnaire data from

repeated cortical arousals that failed to rouse the

1413 students aged 6 to 10. (18).

children, resulting in a paradoxical rise in the

An objectively deep sleep, as assessed by

conscious waking threshold. Because of long-term

EEG, is not the same as a subjectively deep sleep.

overstimulation of the sleep arousal centre by

It's crucial to remember that we're not implying

bladder signals, OAB-associated cortical arousals

https://mmj.mans.edu.eg/home/vol51/iss2/1
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may trigger a change from deep to light sleep but

combination of enuresis alarm and desmopressin is

not total wakefulness.

better to enuresis alarm alone (25).

Subjective signs of poor sleep are growing
in number, and new research demonstrating that

IV. Treatment
Conventional therapies for enuresis include :

enuretic children have higher nocturnal blood



“ Wait and see ” approach.

pressure than normal controls go in the same



Behavioral Therapy.

direction (23). Enuretic children's sleep may be



Enuresis alarm.

"deep," but it is also "poor."



Desmopressin

In conclusion, these investigations show



Tricyclic antidepressants

that children who wet the bed sleep properly (i.e.,



Anticholinergics

the distribution and percentage of various sleep



Combination therapy

stages are within normal norms) but are unable to



Alternative therapies

awaken

in

response

to

nocturnal

detrusor

contractions or bladder fullness. Perhaps the body
prefers enuresis over fragmented sleep by raising
the arousal thresholds.
Different research have looked at what
time of night the enuresis episode occurs, and the
results have been mixed. Early in the evening has
been determined to be the most common time for
NE to occur. Enuretic episodes can occur at any
time during the night, according to these research,
although they are most common during non-rapid
eye movement (non-REM) sleep (24).
The enuresis episode's timing is significant
for two reasons. From a pathophysiological
standpoint, because arousal is often more difficult
and urine output is higher in the early hours of the
night, an enuresis episode is likely to occur during
this time.
The timing of an enuresis episode is also
important from a therapeutic standpoint. It has
been proposed that by delaying the period of
bladder emptying, we can attain dryness by
changing the enuresis episode to a nocturia event.

Because enuresis is self-limiting, one
therapeutic approach is to watch and wait for the
natural history of the condition to play out. A
cautious "wait and see" approach is appropriate.
If the kid and his or her family are unable to
adhere to a therapy, if treatment alternatives are
not feasible given the family's circumstances, and
if there is no societal pressure. However, it is
critical to emphasise in this strategy that the kid
should wear diapers at night to ensure a regular
sleep quality.
The child must be extremely motivated to
engage in a therapy programme that might take
months to complete. Although all bedwetting
children should be given basic counsel, actual
treatment should not normally begin before the age
of six (14).
Regarding Behavioral Therapy : Data
from randomized trials on the efficacy of
behavioral therapy are lacking (26) , but clinical
experience (i.e., level 4 evidence) suggests that
this approach is beneficial (14).

This notion is supported by the fact that a

Published by Mansoura Medical Journal, 2023
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The fundamental goal of behavioral

activated

when

a

sensor,

placed

in

the

therapy centers around the practice of good

undergarment or on a bed pad, detects moisture,

bladder and bowel habits.

with both types demonstrated to be equally



Children should attempt to void regularly

effective. The arousal device is usually an auditory

during the day and just before going to bed

alarm and/or a vibrating belt (30).

for a total of six to seven times daily.




High-sugar and caffeine-based drinks

awakening and therefore change the high arousal

should be avoided, particularly in the

to a low arousal threshold specifically when a

evening hours.

status of full bladder is reached.

Daily ﬂuid intake should be concentrated

Approximately

30%

of

patients

in the morning and early afternoon, and

discontinue enuresis alarms for various reasons,

both ﬂuid and solute intake should be

including skin irritation, disturbance of other

minimized during the evening. Isolated

family members, and/or failure to wake the child

nighttime

without

(31). Adverse effects of alarms include alarm

compensatory increase in daytime ﬂuid

failure, false alarms, disruption of the lives of

consumption, may prevent the child from

other family members, and lack of adherence

meeting his or her daily ﬂuid requirement

because of difficulty using the alarm (28).

ﬂuid

restriction,

and is usually unsuccessful.


The method of action is to repeat the

Alarm treatment should be continued until

Children should be reassured that enuresis

the child has had a minimum of 14 consecutive dry

is not their fault, and children should not

nights (14). Children who do not continue to

be punished for bedwetting, because this

improve after 6 weeks of alarm training are

practice is often counterproductive (27).

unlikely to become completely dry with this

Alarm training has been shown to be the

technique and alternative interventions may be

most effective long-term therapeutic modality in

warranted (32).

the treatment of MSE (28). The response is more

Therapy with the alarm can be reinitiated

gradual and sustained than for desmopressin, with

for relapse (more than two wet nights in 2 weeks).

approximately two-thirds of children becoming dry

Children who relapse after discontinuation of the

during active treatment and nearly one-half

alarm usually can achieve a rapid secondary

remaining dry after treatment completion (28).

response because of preconditioning as a result of

In a large, multisite study of 2861 enuretic
children (5 to 16 years of age), the overall success

the first treatment program (33).
Desmopressin

(1-desamino-8-D-arginine

rate of bell-and-pad alarm therapy was 76%,

vasopressin [DDAVP]) is a synthetic analogue of

irrespective of age (29).

ADH released by the posterior pituitary gland that

Alarms have been used since the 1930s,

reduces urine production by increasing water

but exactly how the alarm works remains

reabsorption

by

the

collecting

tubules.

somewhat of a mystery. Enuresis alarms are

Desmopressin is fairly easy to administer, and its
clinical effects appear immediately, with a serum

https://mmj.mans.edu.eg/home/vol51/iss2/1
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half-life of approximately 2 to 3 hours when taken
in oral form.

However,

the

relapse

rate

after

discontinuation is high (60% to 70%) (37). In

The main safety issue is the risk for water

contrast with the enuresis alarm , treatment effects

intoxication with resultant hyponatremic seizures,

were not sustained after discontinuation of therapy,

so the drug should be taken with excessive ﬂuids.

with a relapse rate of 65% versus 46% with

This risk seems to be somewhat higher with the

DDAVP versus the alarm, respectively (35). The

intranasal form, which has a prolonged half-life,

response to desmopressin should be assessed

and thus use of the spray is discouraged (34).

within 2 weeks. Treatment should be continued if

Treatment should be interrupted during episodes of

there is a positive response (e.g., smaller wet

ﬂuid and/or electrolyte imbalance (e.g., fevers,

patches, fewer wetting episodes) (31). When

vomiting or diarrhea, vigorous exercise, or other

DDAVP is administered daily, we generally give

conditions

patients regular scheduled drug holidays of

associated

with

increased

water

consumption).

approximately 1 week every 3 to 6 months to

The usual starting dose is 0.2 mg orally 1

assess whether the medication is still needed.

hour before bedtime, and the drug can be titrated

Monotherapy with anticholinergic drugs,

up incrementally by 0.2 mg to a maximum dose of

such as oxybutynin or tolterodine, has been

0.6 mg at bedtime. Children are instructed to void

demonstrated not to be effective as a first-line

directly before going to bed. Fluid intake is

treatment for MSE (38). Anticholinergics clearly

reduced at the time of ingestion, with absolutely no

do have a role is combination therapy in the

more ﬂuids until morning, decreasing the risk for

treatment of children who are refractory to

significant hyponatremia to virtually zero (35).

DDAVP monotherapy.

Desmopressin is most efficient in children

There is some evidence that nocturnal

with nocturnal polyuria (defined by the ICCS as

detrusor overactivity (especially without nocturnal

nocturnal urine production >130% of expected

polyuria) plays a role in the pathogenesis of

bladder capacity for age) and normal bladder

enuresis and therefore makes anticholinergics an

reservoir function (maximum voided volume

attractive pharmacotherapeutic option (39).

>70% of expected bladder capacity for age) (36).

Given the efficacy and safety of enuresis

There is a wide range of efficacy among

alarms and DDAVP, TCAs (e.g., imipramine,

studies, most likely because of heterogeneous

amitriptyline, and desipramine) are considered a

patient populations (MSE vs. NMSE), differences

third-line treatment for therapy-resistant MSE.

in

concomitant

therapy

TCAs have been demonstrated to decrease

recommendations, and differences in the dosage or

the amount of time spent in REM sleep, stimulate

formulation of DDAVP, without taking into

ADH secretion, and relax the detrusor muscle via

account

Overall,

weak anticholinergic properties. Its anti-enuretic

approximately 30% of patients achieve total

effect has been theorized to be less likely because

dryness, and another 40% exhibit a significant

of its action at the kidney or bladder level and

decrease in nighttime wetting (14).

more likely a result of noradrenergic stimulation at

nocturnal

behavioral

urine

volume.

Published by Mansoura Medical Journal, 2023
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the brainstem, specifically the locus coeruleus

gastrointestinal discomfort, and neutropenia were

(40).

observed (42).
Level 1 evidence demonstrates that,

compared with placebo, TCAs are more effective

V. Fluoxetine Pharmacological properties

at reducing the number of wet nights and at

Fluoxetine, the first SSRI approved in the

achieving 14 consecutive dry nights (i.e., cure) but

United States for the treatment of MDD, was made

essentially become ineffective once treatment is

commercially available in 1987.

discontinued.

U.S. Food and Drug Administration

The response to imipramine should be

(FDA) and the U.K. Medicine and Health Care

assessed after 1 month. If there is no improvement

Products Regulatory Agency (MHRA) maintain

after 3 months, it should be discontinued as a

that an acceptable risk/benefit relationship exists

gradual taper (as is done with other TCAs).

for fluoxetine for use in the pediatric population

As is the case with other pharmacotherapy

for depression (43).

for enuresis, we give patients a drug holiday every

Fluoxetine has no or negligible influence

3 to 6 months, gradually tapering the dose over a

on the ability to drive and use machines.

2-week period (40).

Fluoxetine

Adverse effects of TCA therapy are

has

been

shown

not

to

affect

psychomotor performance in healthy volunteers.

relatively uncommon. Approximately 5% of

Fluoxetine is a selective inhibitor of

children treated with TCAs develop neurologic

serotonin reuptake. SSRIs inhibit the serotonin

symptoms, including nervousness, personality

transporter (SERT) at the presynaptic axon

change, and disordered sleep. TCAs (as with other

terminal.

antidepressants) are required by the FDA to carry a

amount of serotonin (5-hydroxytryptamine or

black box warning regarding the possibility of

5HT) remains in the synaptic cleft and can

increased suicidality, particularly in individuals

stimulate postsynaptic receptors for a more

with preexisting depressive symptoms.

extended period (44) .

The most serious adverse effects of TCAs
involve

the

increased

Unlike other classes of antidepressants,
SSRIs have little effect on other neurotransmitters,

myocardial

such as dopamine or norepinephrine, so they have

depression, particularly in cases of overdose (41).

relatively fewer side effects than TCAs and

Before initiation of therapy with a TCA, a

MAOIs due to fewer effects on adrenergic,

thorough

cardiac

cholinergic, and histaminergic receptors.

syncope)

and

disturbances

history

and

(e.g.,

cardiac

palpitations,
(e.g.,

The mean fluoxetine concentration in

arrhythmias, sudden cardiac death) should be

children is approximately 2-fold higher than that

obtained with a baseline electrocardiogram to rule

observed in adolescents. Steady-state plasma

out a prolonged QT interval if history or physical

concentrations are dependent on body weight and

examination raises suspicion. Common side effects

are higher in lower-weight children. As in adults,

of

fluoxetine accumulated extensively following

dizziness,

family

system:

an

cardiac

conduction

cardiovascular

By inhibiting SERT,

headache,

history

mood

https://mmj.mans.edu.eg/home/vol51/iss2/1
DOI: 10.21608/mjmu.2022.103268.1045
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multiple oral dosing; steady-state concentrations

non-selective monoamine oxidase inhibitors (e.g.

were achieved within 3 to 4 weeks of daily dosing.

iproniazid) or in combination with metoprolol used
in cardiac failure.

Dose
The starting dose is 10 mg/day. Dose

Side effects

adjustments should be made carefully, on an

The safety and effectiveness in pediatric

individual basis, to maintain the patient at the

patients <8 years of age in Major Depressive

lowest effective dose. After one to two weeks, the

Disorder and <7 years of age in OCD have not

dose may be increased to 20 mg/day. If no clinical

been established.

benefit is achieved within 9 weeks, treatment
should be reconsidered.

The most commonly reported adverse
reactions in patients treated with fluoxetine were
headache, nausea, insomnia, fatigue and diarrhea.

Withdrawal symptoms (seen on discontinuation

Undesirable effects may decrease in intensity and

of fluoxetine)

frequency with continued treatment and do not

Abrupt discontinuation should be avoided.
When stopping treatment with fluoxetine, the dose

generally lead to cessation of therapy.


should be gradually reduced over a period of at
least one to two weeks in order to reduce the risk

QT

interval

prolongation

and

ventricular arrhythmia : rare


of withdrawal reactions.

Serotonin

syndrome

(rare):

particularly when given in combination

If intolerable symptoms occur following a

with other serotonergic (among others

decrease in the dose or upon discontinuation of

L-tryptophan) and/or neuroleptic drugs.

treatment, then resuming the previously prescribed

It is characterized by clusters of

dose may be considered. Subsequently, the

symptoms

such

physician may continue decreasing the dose, but at

tachycardia,

hyperthermia,

a

myoclonus,

autonomic

more

gradual

disturbances,

sleep

rate.

Dizziness,

disturbances

sensory

as

flushing,
rigidity,
instability,

(including

gastrointestinal symptoms (e.g., nausea,

insomnia and intense dreams), asthenia, agitation

vomiting and diarrhea) with possible

or anxiety, nausea and/or vomiting, tremor, and

rapid fluctuations of vital signs, mental

headache are the most commonly reported

status changes including confusion,

reactions. Generally, these symptoms are mild to

irritability and agitation progressing to

moderate, self-limiting and usually resolve within

delirium.


2 weeks.

Hemorrhage (rare): fluoxetine, may
increase the risk of bleeding reactions.

Contraindications

Concomitant

Hypersensitivity to the active substance or
to

any

of

the

excipients.

Fluoxetine

use

of

aspirin,

nonsteroidal anti-inflammatory drugs,

is

contraindicated in combination with irreversible,
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In that study, a 15-year-old boy with a

warfarin, and other anti-coagulants may
add to this risk.

history of primary nocturnal enuresis (occurred 6



Psychomotor restlessness, anxiety.

nights per week) and a positive family history, first



Rash and allergic reactions: Most

presented for therapy for depressive disorder and

patients improved promptly with

obesity. He was prescribed 25 mg of imipramine

discontinuation of fluoxetine and/or

per day to begin with. His weight increased after

adjunctive treatment with

two weeks, and he was diagnosed with essential

antihistamines or steroids, and all

hypertension. He was prescribed 40 mg of

patients experiencing these reactions

fluoxetine per day to address dysthymia and

were reported to recover completely.

obesity. Two weeks later, the patient noticed that

Weight loss: Weight loss may occur in

his

patients taking fluoxetine, but it is

experienced one episode of enuresis every third to

usually proportional to baseline body

fourth week after 24 weeks of fluoxetine 40 mg.

weight.

He was weaned off and then kept off fluoxetine for





Sexual

dysfunction:

enuresis

had

completely

resolved.

He

Includes

eight weeks, which resulted in an increase in

ejaculation

failure,

ejaculation

enuresis to once a week. His mental state

dysfunction,

premature

ejaculation,

continued to improve gradually, but his weight
returned to basal. He was put on fluoxetine 40 mg

retrograde ejaculation.

daily for the following 8 weeks, with the number
of enuretic episodes reduced to once every 4

VI. History of using Fluoxetine for MSE
The effect of drugs which manipulate

weeks.
After that, it has been reported that

serotonin levels such as selective serotonin
reuptake inhibitors (SSRIs) on urination has been

children

noted in recent literature (45).

depression, and nocturnal enuresis received relief

MacLean,

in

1960,

while

treating

psychiatric

diseases,

mainly

of enuretic symptoms with some SSRIs.
Feeney, in 1997, used fluoxetine (Prozac)

emotional problems in a patient, unexpectedly
noticed that imipramine (a tricyclic antidepressant

with

to treat enuretic symptoms in 2 cases (48).
The first patient was a 13-year-old boy

drug) improved the patient’s enuresis (46).
Mesaros , in 1993, while treating a patient

who had anxiety, depression, and ADHD. He also

for dysrythmia, also unexpectedly discovered the

suffered from primary nocturnal enuresis. He was

therapeutic effect of fluoxetine on nocturnal

given fluoxetine 20 mg orally once daily, and his

enuresis (47) . The Previous studies – before that

enuresis was completely resolved within the first

study - had shown fluoxetine to be somewhat

month of treatment. He was observed for a year

efficacious for obesity and depressive disorders

while on fluoxetine, and he remained symptom-

but not for enuresis in adolescents.

free.
In the second case, an 11-year-old girl was
diagnosed with depression, an eating disorder, and

https://mmj.mans.edu.eg/home/vol51/iss2/1
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ADHD. She had primary nocturnal enuresis and a

(50). Then, many trials reported that fluvoxamine

prior negative urological workup. She had a total

or paroxetine were effective and safe for children

cure of enureric symptoms two weeks after

with MNE and no psychiatric disease.

beginning a regimen of fluoxetine 20 mg orally

Kano, in 2001, investigated The effect of

daily. She continued to exhibit an improvement in

fluvoxamine in 18 children (7 girls, 11 boys) aged

enuretic symptoms after 9 months of therapy with

between 7 and 13 years with a diagnosis of

fluoxetine 40 mg.

monosymptomatic nocturnal enuresis and no

Sprenger , in 1997, used sertraline to treat

psychiatric diseases (51).

a 13year-old male who presented with history of

All patients were treated with motivation

irritable, angry, and depressed mood, initial and

therapy, conditional therapy, and bladder retention

middle insomnia, decreased energy, and impaired

+ training before pharmacological therapy, but

concentration (49).

these were not effective. They also administered

The patient reported a minor improvement

desmopressin in 11 of 18 patients at a dose of 10 to

in mood after one week, but also noticed that

20 μg intranasally at bedtime for 3 months. In 8

enuresis had improved to once every two weeks.

(73%) of these 11 patients, the frequency of

His depression symptoms took around 4 weeks to

nocturnal enuresis decreased.

totally resolve. After 5 months of sertraline 50 mg

Fluvoxamine was effective in 14 (78%) of

daily, the patient's enuresis has resolved and his

18 patients. The effectiveness rate of fluvoxamine

depressed symptoms have significantly improved.

was similar to that of desmopressin. Fluvoxamine

That patient's behavior was considerable
because of many reasons. First, the patient's

had no serious adverse effects in that small case
study .

response was fairly strong, ranging from nearly

Toren and collegues were the first to

every night bedwetting to only once every two

evaluate the efficacy of Fluvoxamine in the

weeks when he forgot to take his prescription.

treatment of enuresis in children and adolescents

Second, the enuresis was unknown to the

by an open label pilot study (52). In their case

physician prior to initiating the sertraline, and the

series, no improvement in the mean voiding

sertraline was initiated for the patient's mood

frequency of patients was observed. Conversely, 4

disturbance rather than his enuresis. Third, the

of 9 patients showed a trend toward an increase in

patient's antienuretic reaction was significantly

the frequency of enuresis during treatment. The

faster than his antidepressant response. This study

author concluded that ﬂuvoxamine had no

might support the presence of a serotonergic

antidiuretic properties.

mechanism in, which could be at least relatively

However, the small number of subjects

independent of the serotonergic mechanism in

and mixed target population of the patients should

mood disorders.

be considered (enuresis as the only focus of

Murray, in 1997, used paroxetine to treat
enuretic symptoms in another case with attention-

clinical attention and enuresis as comorbid to
another psychiatric disorder) (52).

deficit disorder and poor gross motor coordination
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In 2014, the efficacy of sertraline in

enuresis, with at least 7 wet nights out of 14, and

treating adolescents with PME refractory to

had all attempted but failed therapy with

desmopressin at the maximal dosage of 0.6 mg per

desmopressin,

night was evaluated (53). The trial involved 25

anticholinergics.

patients ranging in age from 13 to 18 years (mean

monosymptomatic nocturnal enuresis were also

± SD = 15.48 ±1.5 yrs.). For 12 weeks, the patients

involved. The patients were treated over three

were instructed to take one sertraline (50 mg) oral

four-week periods: one with reboxetine 4 mg and

pill after meal every morning. The medication was

desmopressin 0.4 mg, one with reboxetine 4 mg

tapered by 25 mg every two weeks at the ending of

and placebo, and one with double placebo.

enuresis

alarms,

Patients

and

with Non-

the third month. The final follow-up appointment
One patient obtained complete response

occurred six months following the end of therapy.

with reboxetine in monotherapy. Three patients
After 6 weeks of therapy, there was a

were intermediate responders, while the remaining

significant decrease in the mean number of wet

13

were

non-responders.

The

number

of

nights (P=0.01). Nine months after starting

intermediate responders was five throughout

sertraline, the overall number of responders was 18

therapy with reboxetine and desmopressin, leaving

out of 25 (72 %). Twelve individuals had a

12 children non-responders. There were no

complete response, while six had a partial

complete responses to the combined treatment.

response. However, after a 6-month off-sertraline

There was no response to double placebo treatment

follow-up, they discovered considerable decrease

in any of the participants.

in the response rate compared to the initial results,

A small number of patients experienced

and 4 (16%) patients relapsed. This decline

side effects, although they were not serious. Six

throughout follow-up shows that sertraline may

individuals

have a limited effectiveness and its impact may

receiving reboxetine monotherapy, whereas three

progressively decreased over time.

experienced side effects while receiving reboxetine

suffered

adverse

effects

when

Only three patients had mild adverse drug

in combination with desmopressin. The most

effects. Patients who were affected, experienced

common negative effects were mood fluctuations

headaches and nausea. The small sample size,

and, to a lesser extent, sleeping issues. All negative

short follow-up duration, and absence of placebo

effects were completely and quickly reversible,

control are the primary drawbacks of this study.

and the majority were moderate and temporary.

In 2016, A randomized placebo-controlled

The study concluded that reboxetine

trial with a double-blind cross-over design was

appeared to be less effective than imipramine,

done to compare desmopressin with reboxetine (a

raising the question of whether imipramine's

selective norepinephrine reuptake inhibitor) (54).

serotoninergic activity adds to the substance's

The study included 18 individuals ranging in age

efficacy, given that both medications have

from 7 to 21 years. Seventeen patients completed

noradrenergic properties. The small sample size

the study. They were all suffering from severe

was the study's major limitation.
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raphe neurons. Stimulation of 5-HT1A receptors

VII. Effect of fluoxetine on sleep
Serotonin is synthesized from the amino
acid L-tryptophan

by

the enzyme

tryptophan

via systemic administration of agonists has
repeatedly been shown to increase waking.

hydroxylase. This enzyme is only present in

Pharmaco-EEG analysis had shown mild

serotonergic neurons. The immediate serotonin

encephalotropic and activating effects in normals

precursor 5-HTP is the first step. 5-HTP

(decreased slow activity) (59) . There was a dose-

decarboxylase catalyses the conversion of 5-HTP

dependent rise in plasma levels up to the 4th to 6th

to 5-HT or serotonin. This conversion can also

hour, followed by a slow decline, consistent with

occur outside the serotonergic neurons. Serotonin

the reported long half-life. Maximal CNS efficacy

is mostly converted to 5-HIAA by the liver. The

occurred between the 8th and 10th hours postdrug.

first step in metabolism is the oxidation by

In a pilot PSG study, 9 depressed patients

monoamine oxidase to the corresponding aldehyde

were tested before and after treatment with an

(55)

initial dose of 20 mg fluoxetine. If remission did
Serotonin is mainly found in the enteric

not occur, the dosage was increased to up to 40 mg

nervous system which is located in the GIT.

(60). After treatment, sleep stage 1 and REM

However, it is also synthesized in the central

latency (the time span between the start of sleeping

nervous system (CNS), particularly in the Raphe

and the start of REM sleep) were increased, and

nuclei located in the brainstem, Also, serotonin is

the REM percentage was decreased. It seems that

stored in blood platelets and is released during

sleep shifted from deeper (non-REM stages 2, 3)

agitation and vasoconstriction, where it works as

to lighter stages with more wakefulness. Non-

an agonist to other platelets.

REM-sleep eye movements were observed in sleep

In 1976, researchers published the first

stage 1.

trial of unit recordings from the dorsal raphe

In a PSG study, 9 depressed patients

nucleus region in spontaneously sleeping cats (56).

receiving 10–80 mg fluoxetine were compared to 6

The serotonergic neurons were most active when

unmedicated

awake, and their activity decreased throughout

patients showed prolonged REM latency, and

SWS to practically complete stoppage of firing

significantly more eye movements and arousals

during REM sleep. It was also discovered that

during nonREM sleep. Eye movement and

stimulating the dorsal raphe nucleus caused

arousals were significantly correlated (61).

wakefulness (57).

depressed

patients.

Fluoxetine

Thirty-four patients with major depression

5-HT2 receptors are thought to influence

were treated with either fluoxetine 60 mg or

thalamic activity toward the single spike activity,

amitriptyline150 mg in a double-blind trial. Both

i.e. waking. As a result, serotonin acting on 5-HT2

drugs showed similar antidepressant effects, but

receptors in the thalamus may promote single

fluoxetine caused significantly fewer adverse

spike activity and awakening (58). The 5-HT1A

effects. Concerning sleep, patients treated with

receptors are located postsynaptically on many

fluoxetine showed an increase in the number of

neurones, as well as somatodendritically on dorsal
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stage shifts and awakenings. REM sleep was

nuclei (Onuf’s nuclei) receive a dense serotonergic

significantly decreased (62).

input from the raphe nuclei (66).

In summary , Regarding PSG measures,

Multiple 5-HT receptors have been found

fluoxetine increased the number of awakenings ,

at sites where afferent and efferent impulses from

lengthened sleep stage 1 and REM latency, and

and to the LUT are processed. The main receptors

reduced slow-wave sleep and REM sleep. Some

shown to be implicated in the control of

difficulties for instance concerning sleep onset and

micturition are the 5-HT1A, 5-HT2, and 5-HT7

sleep continuity were most pronounced in the

receptors.

initial days of treatment and decreased thereafter
(adaptation phenomena).

Activation of the central serotonergic
system can suppress voiding by inhibiting the

Objective awakening quality (attention,

parasympathetic excitatory input to the urinary

concentration, fine motor activity, reaction time

bladder, and 5-HT elicits a prolonged activation of

performance) in normals showed no decrements

thoracic

after SSRIs as has been described with the

Stimulation of the raphe nuclei in the cat inhibits

classical

reﬂex bladder activity (67).

sedative

amitriptyline-type

antidepressants (63) .

sympathetic

preganglionic

neurons.

However, in different species, serotonin

Subjective sleep and awakening quality as

(5-HT) may have varying functions in the central

rated by observer- and self-rating scales in normal

nervous control of bladder activity. For example,

volunteers hardly exhibited any changes after

activation of 5-HT1A receptors facilitates reﬂex

SSRIs, while in patients an improvement was

bladder activity in rats (65).

observed.

It has been speculated that selective

The main 5-HT center in the brain, the

serotonin reuptake inhibitors (SSRIs) may be

dorsal raphe nuclei (DRN), sends inhibitory

useful for treatment of DO/OAB. On the other

afferents to pontine generators of REM sleep.

hand, there are reports suggesting that the SSRIs in

During wakefulness and non-REM sleep the 5-HT

patients without incontinence actually can cause

neurons in the DRN inhibit pontine neuronal

incontinence, particularly in the elderly, and one of

generators of REM sleep. Regarding deep-sleep

the drugs (sertraline) seemed to be more prone to

stages, the potent 5-HT reuptake inhibition by

produce urinary incontinence than the others.

SSRIs may lead to an activation of the 5-HT2c
receptor and therefore decrease deep sleep (64) .

Patients exposed to serotonin uptake
inhibitors had an increased risk (15 out of 1000
patients) for developing urinary incontinence. So
far, there are no RCTs demonstrating the value of

VIII. Effect of fluoxetine on Bladder
Spinal reﬂex circuits involved in voiding
function

have

hydroxytryptamine

a

dense
[5-HT])

serotonergic
innervation

SSRIs in the treatment of DO/OAB.

(5(65).

Lumbosacral autonomic, as well as somatic, motor

In a bladder-irritated model, Duloxetine,
which

is a

combined

norepinephrine

and

serotonin reuptake inhibitor, was demonstrated to
enhance the neuronal activity of the urethral

https://mmj.mans.edu.eg/home/vol51/iss2/1
DOI: 10.21608/mjmu.2022.103268.1045

14

Abdelazim et al.: Role of Fluoxetine in primary Monosymptomatic Nocturnal enuresis.
75

fluoxetine in primary Monosymptomatic Nocturnal enuresis

sphincter and the bladder (68). Duloxetine seems

case reports of fluoxetine-induced SIADH in the

to have bladder and sphincter effects and has been

literature (71).
SIADH is an apparently rare complication

recommended for the management of stress and

of the use of fluoxetine. One study reported three

urgency incontinence.
Duloxetine enhances neural activity to the

cases of the fluoxetine-induced syndrome of

External Urethral Sphincter and inhibits bladder

inappropriate secretion of antidiuretic hormone

activity in cats via Central nervous effects. In a rat

(SIADH). All three cases occurred in elderly

experiment, duloxetine improves the urethral

psychiatric inpatients treated for depression with

continence reflex during sneezing, as demonstrated

standard doses of fluoxetine within one month of

by an

in sneeze-induced pressure

starting the medication. All three patients were

responses at the middle urethra, however the effect

clinically symptomatic of SIADH. In all three

appears

patients the medication was ceased and fluid

increase
to

be

mediated

mostly

by

α1-

restriction commenced. One patient required

adrenoceptors.
In a placebo-controlled trial involving women
with

OAB,

duloxetine

demonstrated

intravenous saline (71) .

a

All three patients recovered fully within

voiding

and

three weeks. So that study concluded that The

prolongation in

daytime

symptoms of hyponatraemia due to fluoxetine-

voiding intervals, and improvement in quality-of-

induced SIADH may be difficult to distinguish

life

from

significant improvement in
incontinence

events,

scores when

compared

to

placebo.

Urodynamic investigations revealed no statistically

the

symptoms

of

depression,

unless

appropriate laboratory investigations are made.

significant improvements in maximal cystometric
capacity or DO volume threshold (69).

X. Effect on emotional stress
One of the important etiologies of MNE

IX. Effect of fluoxetine on ADH

may be emotional stress, especially in secondary

In animal studies , Fluoxetine caused a

MNE. Children with MNE had an abnormality of

significant increase in AVP concentrations in

the stress barometer (i.e. high values of urinary 17-

peripheral plasma as well as a significant increase

OHCS and low values of 17-KS-S/17-OHCS).

of AVP concentrations in hypophysial portal

Urinary 17-OHCS acts as a stress barometer and

plasma (70). These data suggest that increased

was related to the ‘wear and tear’ of stress, and 17-

secretion of ACTH induced by fluoxetine is

KS-S acts as a stress barometer and was related to

mediated, at least in part, by an increase in the

‘repair and recovery’. Therefore, this stress

hypothatanuc secretion of both CRF and AVP.

barometer becomes a marker of a personal reaction

Peripheral plasma AVP concentrations in

to emotional stress. Many reports illustrated that

rats treated with fluoxetine increased 4-fold within

children with MNE in whom antidepressive drugs

20 min (P < 0.05) and continued to increase

were effective had an abnormality of the stress

throughout the collection period. Also, There were

barometer (i.e. high values of 17-OHCS and low
values of 17-KS-S/17-OHCS).
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In one study, the relationship between the

Enuresis is thought to be caused by a maturational

stress barometer and the effect of fluvoxamine in

lag in the final development of bladder control.

children with NE was examined excluding patients

The bladder, kidney, and brain are the three organ

with psychiatric diseases (45).

systems involved in the pathophysiology of

Fluvoxamine showed a complete effect
(no wet nights) in 14 of 40 children (35%) with

enuresis. The most significant pathophysiological
component is the high arousal threshold.

primary MNE and an incomplete effect (a greater

There are many theories of mechanism of

than 50% reduction in the number of wet nights in

action of fluoxetine for the treatment of MSE. The

18 of 40 children (45%). Fluvoxamine showed a

first one is that changes in serotonin levels have

complete effect in three of seven children (43%)

specific

with secondary MNE, and an incomplete effect in

suppresses ureteral peristalsis and micturition by

three of seven patients (43%).

interacting with spinal reflexes, principally via 5-

effects

on

micturition.

Serotonin

Fluvoxamine produced a greater than 50%

HT3 receptor agonism. The second theory is the

reduction in the number of wet nights in 26 of 28

effect of SSRI, Fluoxetine on arousal state during

children

and

sleep. Many studies confirm that fluoxetine leads

abnormality of the stress barometer, and in six of

to increasing of the number of awakenings,

six children (100%) with secondary MNE.

lengthening of sleep stage 1 and REM latency, and

(93%)

with

primary

MNE

One patient had headache, one had nausea

reduction of the slow-wave sleep and REM sleep.

and one had both headache and nausea, but these

The third theory is the association between

adverse

continued

fluoxetine and ADH. Several lines of study have

treatment with fluvoxamine. No serious clinical

suggested that fluoxetine increases plasma ADH in

adverse effects or abnormal laboratory data in

both humans and animals. The fourth theory is the

blood or urine were noted.

effect on emotional stress. One of the important

effects

disappeared

with

In conclusion, fluvoxamine might be

etiologies of MSE may be emotional stress,

useful clinically for the treatment of children with

especially in secondary MSE. Fluoxetine was

MNE and an abnormality of the stress barometer

associated with a significant decrease in the stress

because fluvoxamine is more effective than

barometers.

imipramine or desmopressin. Our results also
suggest that the stress barometer is useful

Conclusion

the

Fluoxetine, a selective serotonin reuptake

therapeutic effect of fluvoxamine in children with

inhibitor, may be a successful line of treatment for

MNE.

nocturnal

clinically

for

evaluating

enuresis

in

children.

Randomized

controlled trials are encouraged to evaluate the
safety and efficacy of fluoxetine in management of

Results
In this review, we have efficiently
illustrated the feasibility and safety of using

primary monosymptomatic nocturnal enuresis in
children especially in refractory cases.

fluoxetine in management of nocturnal enuresis.
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